CA2446510A1 - Therapeutic agent for tumor of neural origin - Google Patents

Therapeutic agent for tumor of neural origin Download PDF

Info

Publication number
CA2446510A1
CA2446510A1 CA002446510A CA2446510A CA2446510A1 CA 2446510 A1 CA2446510 A1 CA 2446510A1 CA 002446510 A CA002446510 A CA 002446510A CA 2446510 A CA2446510 A CA 2446510A CA 2446510 A1 CA2446510 A1 CA 2446510A1
Authority
CA
Canada
Prior art keywords
protein
amino acid
cells
acid sequence
hub
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002446510A
Other languages
English (en)
French (fr)
Inventor
Hideyuki Okano
Wado Akamatsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Science and Technology Agency
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2446510A1 publication Critical patent/CA2446510A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002446510A 2001-05-24 2001-10-03 Therapeutic agent for tumor of neural origin Abandoned CA2446510A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001-155237 2001-05-24
JP2001155237A JP2002348254A (ja) 2001-05-24 2001-05-24 神経系腫瘍治療剤
PCT/JP2001/008701 WO2002094306A1 (fr) 2001-05-24 2001-10-03 Remedes pour le traitement des tumeurs nerveuses

Publications (1)

Publication Number Publication Date
CA2446510A1 true CA2446510A1 (en) 2002-11-28

Family

ID=18999466

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002446510A Abandoned CA2446510A1 (en) 2001-05-24 2001-10-03 Therapeutic agent for tumor of neural origin

Country Status (4)

Country Link
US (2) US20040147438A1 (enExample)
JP (1) JP2002348254A (enExample)
CA (1) CA2446510A1 (enExample)
WO (1) WO2002094306A1 (enExample)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002220265A1 (en) * 2000-11-03 2002-05-15 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
JP2007516693A (ja) * 2003-06-09 2007-06-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 癌の治療および診断のための組成物および方法

Also Published As

Publication number Publication date
WO2002094306A1 (fr) 2002-11-28
JP2002348254A (ja) 2002-12-04
US20070299031A1 (en) 2007-12-27
US20040147438A1 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
Macmillan-Crow et al. Manganese superoxide dismutase in disease
Selsted et al. Defensins in granules of phagocytic and non-phagocytic cells
US10967038B2 (en) Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
JPH07505124A (ja) ニューロトロフィン活性増強のためのｋ−２５２化合物を含む組成物
JPH05504566A (ja) 生物学的活性を有するペプチドを使用した創傷処置方法
KR20090048382A (ko) Ａｉｍｐ2-ｄｘ2의 억제제를 유효성분으로 포함하는 염증성질환 예방 및 치료용 조성물
HK1210056A1 (en) Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
JP4887143B2 (ja) 癌細胞を選択的に死滅させるＲａｓＧＡＰ由来ペプチド
Zhuo et al. Combination therapy with taurine, epigallocatechin gallate and genistein for protection against hepatic fibrosis induced by alcohol in rats
Xiang et al. C1q/TNF‐related protein 6 (CTRP6) attenuates renal ischaemia‐reperfusion injury through the activation of PI3K/Akt signalling pathway
Liberge et al. Changes in TNFα, NFκB and MnSOD protein in the vestibular nuclei after unilateral vestibular deafferentation
Bessero et al. Role of the c‐Jun N‐terminal kinase pathway in retinal excitotoxicity, and neuroprotection by its inhibition
EP4333875A1 (en) Alpha-1-antitrypsin (aat) in the treatment and/or prevention of neurological disorders
CN107034201B (zh) 表观修饰酶setd2的抗病毒作用及其应用
US20040147438A1 (en) Remedies for nervous tumor
US12138300B2 (en) Methods and compositions for inducing neural plasticity
Ben‐Yehudah et al. IV Administration of L‐GnRH‐PE66 efficiently inhibits growth of colon adenocarcinoma xenografts in nude mice
AU2018301399A1 (en) Compositions and methods for treating myelin disorders
US20090156496A1 (en) Methods and compositions for treating and preventing peripheral nerve damage
WO2020023621A1 (en) Improved weight loss therapy
CN112451683B (zh) Timp-1在制备预防或治疗创伤性脑损伤药物中的应用
US20070185020A1 (en) Methods and compositions for treating disorders of the extracellular matrix
Kaur et al. The Secreted Ly6/uPAR-Related Protein-1 (SLURP1) Protects the Cornea From Oxidative Stress
KR20240086733A (ko) 병인성 비멘틴 발현 유도를 통한 코로나바이러스 감염병 동반 전신경화증 모델 플랫폼
KR20240087587A (ko) Cd82와 brcc3 또는 nlrp3과의 상호작용을 억제하는 제제를 유효성분으로 포함하는 대장염 예방 또는 치료용 약학적 조성물

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued